Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development
Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
Protagonist Therapeutics Elects Chaitan Khosla, Ph.D. to Board of Directors
November 2-4, 2015
December 10-12, 2015
Protagonist Therapeutics Inc.
521 Cottonwood Drive, Suite 100
Milpitas, CA 95035-7404 USA